ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Pembrolizumab, KEYTRUDA 25 mg/m
CT-P51 3.1
Phase 3 small_molecule active
Quick answer
ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Pembrolizumab, KEYTRUDA 25 mg/m for Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer is a Phase 3 program (small_molecule) at Celltrion Healthcare Hungary Kft. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Celltrion Healthcare Hungary Kft.
- Indication
- Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active